Webinar Date/Time: Tuesday, September 26th, 2023 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
How FSP is changing the way studies are outsourced, an investigation into the history, trends and key drivers of success for using functional service providers.
Register Free: https://www.appliedclinicaltrialsonline.com/act_w/clinical-outsourcing-strategies
Event Overview:
Ongoing challenges with cost and time-to-market have created increasing pressures for sponsors to optimize their clinical trial delivery. This webinar explores some of the key headwinds for clinical trial delivery in addition to the tools, technologies and processes that are being leveraged to address these. The evolution of outsourcing strategies is discussed along with a focus on diverse Functional Service Provider (FSP) models.
These FSP delivery models will be discussed, looking at how they can be leveraged to address specific needs and requirements, their pros and cons, as well as the key deciding factors for how and when they should be employed.
Key take-aways
Speakers:
Ian Pemberton
VP, Clinical FSP
IQVIA
Ian has over 26 years in clinical research and has worked in Pharma Companies and CROs in that time in a number of operational and leadership roles. Ian has spent the last 16 years working in IQVIA in Clinical, Project Management, Regulatory & Start up roles with the last 3 years leading the setup, implementation and oversight of Clinical FSP Models.
Stephen Evans
VP, Clinical FSP
IQVIA
Stephen leads IQVIA’s large pharma clinical FSP group. He has spent 15 years at IQVIA across a number of clinical development and business development roles and immediately prior to working in Clinical FSP he led IQVIA’s Early Clinical Development unit within Project Leadership.
Register Free: https://www.appliedclinicaltrialsonline.com/act_w/clinical-outsourcing-strategies
What Can ClinOps Learn from Pre-Clinical?
August 10th 2021Dr. Hanne Bak, Senior Vice President of Preclinical Manufacturing and Process Development at Regeneron speaks about her role at the company as well as their work with monoclonal antibodies, the regulatory side of manufacturing, and more.